4.5 Review

High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need

期刊

CELL CHEMICAL BIOLOGY
卷 28, 期 3, 页码 338-355

出版社

CELL PRESS
DOI: 10.1016/j.chembiol.2021.02.015

关键词

-

资金

  1. Medical Research Council (Institute of Genetics and Molecular Medicine)
  2. Anne Forest Fund for Oesophageal Cancer Research
  3. Cancer Research UK Small Molecule Drug Discovery project [C42454/A24892]
  4. Cancer Research UK [C42454/A28596]
  5. Brain Tumour Charity [GN-000676]

向作者/读者索取更多资源

Conventional thinking suggests that designing highly selective molecules for single disease-associated targets can lead to safer and more effective drugs, but high clinical attrition rates challenge this assumption. Integration of emerging phenotypic and pathway profiling technologies can help unravel the mechanism-of-action of phenotypic hits, supporting more efficient drug discovery strategies for complex diseases.
Conventional thinking in modern drug discovery postulates that the design of highly selective molecules which act on a single disease-associated target will yield safer and more effective drugs. However, high clinical attrition rates and the lack of progress in developing new effective treatments for many important diseases of unmet therapeutic need challenge this hypothesis. This assumption also impinges upon the efficiency of target agnostic phenotypic drug discovery strategies, where early target deconvolution is seen as a critical step to progress phenotypic hits. In this review we provide an overview of how emerging phenotypic and pathwayprofiling technologies integrate to deconvolute the mechanism-of-action of phenotypic hits. We propose that such in-depth mechanistic profiling may support more efficient phenotypic drug discovery strategies that are designed to more appropriately address complex heterogeneous diseases of unmet need.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据